AML management: An introduction to VENCLEXTA (venetoclax)
~3 mins
In this video Dr Vinod Pullarkat from the City of Hope National Medical Center, California, US, provides his perspective on the treatment of acute myeloid leukaemia (AML), how VENCLEXTA works in AML and which patients may be suitable for VENCLEXTA treatment.
YOU MIGHT ALSO BE INTERESTED IN...
VENCLEXTA in AML:
An Australian Perspective
~6 mins
VENCLEXTA in AML:
Phase III studies
~6 mins
VENCLEXTA in AML:
Management & mitigation strategies
~5 mins
Contact
Discover more about how we can help you in your practice.
VENCLEXTA PBS information: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML. |
PLEASE REVIEW FULL PRODUCT INFORMATION (PI) BEFORE PRESCRIBING VENCLEXTA. FULL PI IS AVAILABLE FROM ABBVIE PTY LTD BY CALLING 1800 043 460 OR ACCESSED HERE.
AML: acute myeloid leukaemia.
AU-VENA-210109 September 2022